World Investment Advisors Acquires 1,597 Shares of Elevance Health, Inc. $ELV

World Investment Advisors raised its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 6.0% in the 4th quarter, HoldingsChannel.com reports. The fund owned 28,290 shares of the company’s stock after purchasing an additional 1,597 shares during the quarter. World Investment Advisors’ holdings in Elevance Health were worth $9,606,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Sound View Wealth Advisors Group LLC raised its position in shares of Elevance Health by 3.0% during the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,011 shares of the company’s stock valued at $354,000 after acquiring an additional 29 shares during the last quarter. Fulton Breakefield Broenniman LLC raised its position in shares of Elevance Health by 3.6% during the 4th quarter. Fulton Breakefield Broenniman LLC now owns 825 shares of the company’s stock valued at $289,000 after acquiring an additional 29 shares during the last quarter. Perigon Wealth Management LLC raised its position in shares of Elevance Health by 2.2% during the 4th quarter. Perigon Wealth Management LLC now owns 1,371 shares of the company’s stock valued at $481,000 after acquiring an additional 29 shares during the last quarter. Savvy Advisors Inc. raised its position in shares of Elevance Health by 3.2% during the 4th quarter. Savvy Advisors Inc. now owns 979 shares of the company’s stock valued at $343,000 after acquiring an additional 30 shares during the last quarter. Finally, Detalus Advisors LLC raised its position in shares of Elevance Health by 1.8% during the 3rd quarter. Detalus Advisors LLC now owns 1,726 shares of the company’s stock valued at $558,000 after acquiring an additional 31 shares during the last quarter. Institutional investors own 89.24% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on ELV. Sanford C. Bernstein upped their target price on shares of Elevance Health from $384.00 to $424.00 and gave the company an “outperform” rating in a research report on Friday, April 24th. JPMorgan Chase & Co. upped their target price on shares of Elevance Health from $397.00 to $411.00 and gave the company an “overweight” rating in a research report on Tuesday, April 28th. Evercore boosted their price target on shares of Elevance Health from $345.00 to $360.00 in a report on Thursday, April 23rd. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Elevance Health from $332.00 to $363.00 and gave the company a “hold” rating in a report on Thursday, April 23rd. Finally, Guggenheim boosted their price target on shares of Elevance Health from $396.00 to $399.00 and gave the company a “buy” rating in a report on Friday, April 24th. Thirteen equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $384.58.

Elevance Health Price Performance

Shares of ELV stock opened at $399.32 on Thursday. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $412.96. The firm has a market capitalization of $86.72 billion, a price-to-earnings ratio of 16.98, a price-to-earnings-growth ratio of 2.24 and a beta of 0.66. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. The firm has a fifty day moving average of $318.59 and a 200-day moving average of $333.23.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company had revenue of $49.49 billion during the quarter, compared to analyst estimates of $48.21 billion. During the same quarter in the previous year, the business earned $11.97 EPS. The firm’s revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, equities research analysts forecast that Elevance Health, Inc. will post 26.79 earnings per share for the current year.

Elevance Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be issued a $1.72 dividend. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 annualized dividend and a dividend yield of 1.7%. Elevance Health’s payout ratio is 29.26%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.